| Line 36: | Line 36: | ||
*Article about the study: [https://www.revyuh.com/top-news/featured/e-cigarettes-may-help-you-quit-smoking-even-if-you-dont-want-to/ E-cigarettes may help you quit smoking, even if you don’t want to] | *Article about the study: [https://www.revyuh.com/top-news/featured/e-cigarettes-may-help-you-quit-smoking-even-if-you-dont-want-to/ E-cigarettes may help you quit smoking, even if you don’t want to] | ||
*Press Release: [https://www.roswellpark.org/newsroom/202112-daily-vaping-dramatically-ups-quit-rate-heavy-smokers-not-aiming-quit Daily Vaping Dramatically Ups Quit Rate in Heavy Smokers Not Aiming to Quit] | *Press Release: [https://www.roswellpark.org/newsroom/202112-daily-vaping-dramatically-ups-quit-rate-heavy-smokers-not-aiming-quit Daily Vaping Dramatically Ups Quit Rate in Heavy Smokers Not Aiming to Quit] | ||
===2014: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245610/ Effectiveness of the Electronic Cigarette: An Eight-Week Flemish Study with Six-Month Follow-up on Smoking Reduction, Craving and Experienced Benefits and Complaints]=== | |||
*When people, ready to switch to an e-cig, are severely restricted in terms of accessibility of nicotine-containing e-liquids, the success of e-cigs may be endangered. For the e-cig to be and remain successful, it is important that people have easy access to nicotine containing e-liquids. | |||
*“In a series of controlled lab sessions with e-cig-naïve tobacco smokers, second-generation e-cigs were shown to be immediately and highly effective in reducing abstinence-induced cigarette craving and withdrawal symptoms, while not resulting in increases in eCO. Ad libitum use of e-cigs—in between and until six months after the lab sessions—resulted in remarkable reductions in or (biologically confirmed) complete abstinence from tobacco smoking in almost half of the participants who had no intention to quit smoking. Eight months after the start of the study 21% of all participants were completely abstinent from tobacco cigarettes. Similar reduction/cessation rates were obtained with guided versus non-guided switching to e-cigs. Part of the observed efficacy of e-cigs in this study may be related to the fact that they allowed to maintain relatively high blood nicotine levels and showed an excellent experienced benefits/complaints ratio, especially in comparison with continued tobacco smoking”... | |||
*E-cigarette is an attractive long-term alternative and safer source of nicotine to conventional cigarette. Since their invention in 2003, there has been constant innovation and development of more efficient and appealing products. Here we show for the first time that second generation PVs can substantially decrease cigarette consumption without causing significant side effects in smokers not intending to quit. Moreover, overall participants’ perception and acceptance of these products was very good, in particular for those who quit or reduced smoking. Compared to our earlier work with first generation “cig-alikes”, technical problems and difficulties in use familiarization with second generation PVs were negligible. Improved products reliability and attractiveness might have contributed to the very low number of study failures and lost to follow-up and high success rates thus confirming the notion that these products are attractive substitutes for conventional cigarettes. Although large and carefully conducted RCTs will be required to confirm these preliminary encouraging observations, the notion that second generation PVs can substantially decrease cigarette consumption in smokers not intending to quit should be taken into consideration by regulatory authorities seeking to adopt proportional measures for the vapour category | |||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245610/pdf/ijerph-11-11220.pdf PDF Version] | |||
=== 2013: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691171/ EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as Tobacco Cigarettes Substitute: A Prospective 12-Month Randomized Control Design Study] === | === 2013: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691171/ EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as Tobacco Cigarettes Substitute: A Prospective 12-Month Randomized Control Design Study] === | ||
* ECLAT is a prospective 12-month randomized, controlled trial that evaluates smoking reduction/abstinence in 300 smokers not intending to quit experimenting two different nicotine strengths of a popular e-cigarette model compared to its non-nicotine choice. | * ECLAT is a prospective 12-month randomized, controlled trial that evaluates smoking reduction/abstinence in 300 smokers not intending to quit experimenting two different nicotine strengths of a popular e-cigarette model compared to its non-nicotine choice. | ||
* The study consisted of nine visits during which cig/day use and exhaled carbon monoxide (eCO) levels were measured. Smoking reduction and abstinence rates were calculated. Adverse events and product preferences were also reviewed. | * The study consisted of nine visits during which cig/day use and exhaled carbon monoxide (eCO) levels were measured. Smoking reduction and abstinence rates were calculated. Adverse events and product preferences were also reviewed. | ||
edits